Skip to content

Eloralintide

Also called LY3841136 (selective amylin agonist)

Selective long-acting amylin receptor agonist (AMY1R-preferring).

  • TypePeptide
  • FormInjectable
  • Researched forMetabolic & Fat Loss

Where to get Eloralintide

Flawless Compounds
Injectable
Code CAMERON

21+ to enter. The only form sold. Research compound, not approved for human use.

Shop injectable at Flawless Compounds

The short version

  • Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
  • What the evidence isIn phase 2.
  • What to watchSevere headache with visual aura.

How Eloralintide works

Selective long-acting amylin receptor agonist (AMY1R-preferring) — appetite suppression via amylin pathways. More receptor-selective than cagrilintide.

This is the only compound in this cohort whose receptor selectivity ratio is actually published, so start there, because for a receptor-selective drug the ratio is the drug.

In cell lines expressing human receptors, eloralintide preferentially activated the human amylin 1 receptor: 12-fold over the calcitonin receptor and 11-fold over the amylin 3 receptor Briere 2025. Hold those numbers next to what the receptors are. AMY1 is the calcitonin receptor with RAMP1 bolted on; AMY3 is the same core with RAMP3 Boyle 2022.

  • Injectable

On the goal map: Appetite & satiety signaling (Lose fat)

Research on Eloralintide5 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Human clinical evidence

  • In phase 2. Eli Lilly's selective amylin receptor agonist. Early data reported meaningful weight loss with notably low rates of nausea and vomiting compared with GLP-1 agonists — which, if it holds, is the commercially important finding rather than the weight number.

Correlative data

  • No marketed use and no real-world record. The tolerability claim comes from small early cohorts and needs phase 3 scale before it means anything.

How the mechanism reads

  • A selective amylin analog — no GLP-1 activity at all, which is the point. Pramlintide proved amylin agonism causes weight loss twenty years ago.

    Mechanistic
  • Selectivity is the bet on tolerability. If most of the GI burden comes from GLP-1's effect on gastric emptying, then an amylin-only agent should deliver satiety with less nausea — and that is precisely what the early data suggests.

    Mechanistic
  • It also predicts a smaller glycemic effect than a GLP-1, since amylin does not stimulate insulin secretion.

    Mechanistic

Sources

  • Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism 2025 · PMID 41109426
  • Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2025 · PMID 41207310
  • Bhattachar S, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism 2026 · PMID 41559929
  • Boyle CN, Le Foll C, Lutz TA. Mediators of Amylin Action in Metabolic Control. Journal of Clinical Medicine 2022 · PMID 35456307
  • Ghanizada H, et al. Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients. Annals of Neurology 2021 · PMID 33772845
  • Stefanakis K, et al. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism 2024 · PMID 39481534
  • He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine 2022 · PMID 35344001
  • Volcansek S, et al. Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity. Diabetes Therapy 2025 · PMID 40332747
  • Muller TD, et al. Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery 2022 · PMID 34815532

Eloralintide safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Migraine with aura, since amylin analog pramlintide has provoked migraine-like attacks.
  • Insulin use, given amylin-class severe hypoglycemia warnings.
  • Gastroparesis or erratic stomach emptying, which amylin agonism slows further.
  • Pregnancy, as weight-loss appetite drive lowers nutrient intake.
  • Under 18, where amylin-axis appetite suppression is untested.

What’s expected

  • Appetite falls through amylin receptor action.
  • Nausea, with no GLP-1 heart rate increase.
  • Slower gastric emptying.

Watch for

  • Severe headache with visual aura.
  • Vomiting that persists beyond the first days of each change.
  • Sweating and shakiness if used with glucose-lowering drugs.

Labs that tell you it’s working

  • HbA1c: glucose control improves as weight falls.
  • Comprehensive Metabolic Panel: kidney function and electrolytes if intake drops.
  • Insulin (Fasting): AMY1R agonism does not itself raise insulin.
  • Lipid Panel: triglycerides follow weight change.

Selective long-acting amylin receptor agonist (AMY1R-preferring) with no GLP-1 activity, so GLP-1 class risks do not transfer. PMID 41109426 PMID 41207310 PMID 33772845

Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON

Eloralintide FAQ4 common questions

Is Eloralintide approved for human use?
No. Eloralintide is a research compound.
What is Eloralintide researched for?
Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Which labs show whether it's doing anything?
HbA1c; Comprehensive Metabolic Panel; Insulin; Lipid Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for Eloralintide: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what Eloralintide is. Skool covers how it is run.

Free on this page

What Eloralintide is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What Eloralintide is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool